# Measuring the value of managed health care

**Praneet Valodia** 



### Methods to measure value

- Health outcomes
- Benchmarking
- Return on investment
- Trend analysis (using moving average)
- Claims cost versus inflation over time (year to year)
- Other: Total population approach, survival analysis



## **Definition: Health Outcomes**

A scientific discipline that evaluates the effect of health care interventions on patient-related, if not patient specific, economic, clinical and humanistic outcomes

**ISPOR BOOK OF TERMS** 





Difference = Outcome



Value of managed health care

### **Pre-Post intervention: phenytoin**



P. Valodia et al, Benefits of a clinical pharmacokinetic service in optimizing phenytoin use in the Western Cape. SAMJ.1998,88:873-875



#### **PRE-AND POST INTERVENTION**





#### Population vs Individual Health Outcomes Assessment



### **Asthma: Health Outcomes**

#### Clinical

- Categorization of uncontrolled, partially control and controlled patients
- Frequency of symptoms
- Severity of symptoms
- Number of symptoms
- Number of asthma attacks
- Number of emergency room visits.
- Number of asthma related hospital days
- Number of nebulisations
- Number GP consults
- Number specialists consults



#### Economic

- Savings due to reduced hospitalizations
- Savings due to reduced emergency room visits
- Savings due to decrease hospital nebulisations
- Savings due to decrease in consultation costs
- Savings due to decrease specialist visits
- Savings due to increased productivity (less absenteeism)

#### Humanistic

- Improved quality of life
- Improved patient satisfaction
- Improved compliance
- Improved understanding of inhaler use
- Improved understanding of personal treatment plan
- Improved ability to use as peak flow meter
- Smoking cessation
- Avoidance of trigger
  factors
- Increase use of a spacer device when required

### Challenges with measuring health outcomes

- Definition of health outcomes
- Careful planning of data collection
- Availability of good baseline information
- Selection bias
- Missing data points
- Validation of ICD10 and CPT codes
- Matching of control groups
- Regression to the mean
- Clinical and statistical differences
- Inter- and intra-scheme variability



## Challenges

- A priori specification of confounding variables
- Interpretation denominator effect, RTTM
- Development of questionnaires sensitive to changes over time
- Integration and automation of all systems
- Development of intelligent health systems
- Disease specific clinical measurement
- Not all information is extractable
- Develop impactibility models



# **Project phases**

- Phase 1: report on claims data
- Phase 2: report on clinical data
- Phase 3: development of measurement tools (questionnaires) for health outcomes reporting
- Phase 4: development of economic and probability models



### Methods

- Pre –post intervention
- intervention vs control group





# Way forward

- Form industry group to develop methods
- Provide guidelines to industry to measure outcomes
- Implement a phased approach

